Effect of semaglutide 2.4 mg once weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction

This study is to look at how well a new medicine called semaglutide works compared to placebo medicine in lowering body weight and the symptoms of heart failure. Heart failure is a condition in which the heart muscle is unable to pump enough blood to meet the body’s nutrition and oxygen needs. If the heart pumps normally but is too stiff to fill properly, the condition is known as heart failure with preserved ejection fraction (HFpEF). Obesity is when your body has too much body fat and is defined when your weight is too high compared to your height. Patients with HFpEF often take medicine to lower the symptoms of HFpEF such as swollen limbs due to fluid build-up. People living with obesity are most often treated with changes to food intake and physical activity. But this does not result in a weight loss for all people. Studies show that semaglutide may help lower body weight and by lowering weight it may also reduce some of the symptoms from HFpEF. We will test this in this study.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Heart failure,preserved ejection fraction
• Age: Between 18 Years - 99 Years
• Gender: All